Use of nivolumab for colon cancer with Lynch syndrome

Lynch syndrome (LS), which occurs as a result of the defects in DNA mismatch repair, is characterized by an increased risk of colon, endometrial and urinary tract cancers. It is known that in case of colorectal cancer, the presence of high-frequency microsatellite instability (MSI-H) is associated w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	G. A. Khakimov, A. A. Tryakin, G. G. Khakimova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	immunotherapy colon cancer microsatellite instability anti-pd-1 monoclonal antibodies nivolumab pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b99da209ccc44f37985e2d2943ad2e92
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b99da209ccc44f37985e2d2943ad2e92
record_format	dspace
spelling	oai:doaj.org-article:b99da209ccc44f37985e2d2943ad2e922021-11-30T17:03:34ZUse of nivolumab for colon cancer with Lynch syndrome1815-14341815-144210.26442/18151434.2020.3.200350https://doaj.org/article/b99da209ccc44f37985e2d2943ad2e922020-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/52595/36040https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Lynch syndrome (LS), which occurs as a result of the defects in DNA mismatch repair, is characterized by an increased risk of colon, endometrial and urinary tract cancers. It is known that in case of colorectal cancer, the presence of high-frequency microsatellite instability (MSI-H) is associated with better survival rates, independent of other prognostic factors, including the stage of tumor development. Thus, in stage II sporadic colorectal cancer, MSI-H occurs in 22% of cases, in stage III in 12% of cases, and in stage IV only in 2% of cases. Regardless of the type of the tumor, immunotherapy using checkpoint inhibitors has been approved for treating patients with unresectable or metastatic tumors with deficient DNA mismatch repair (dMMR), this fact can be used as an approach to treatment patients with LS. The article describes the clinical observation of the patient with germline mutation in MLH1 gene, suffering from multiple primary malignancies of the colon, who has been receiving nivolumab for 26 months. This observation demonstrates the success of immunotherapy after sixth-line chemotherapy, showing the potential control of tumor growth in patients with LS.G. A. KhakimovA. A. TryakinG. G. KhakimovaIP Habib O.N.articleimmunotherapycolon cancermicrosatellite instabilityanti-pd-1 monoclonal antibodiesnivolumabpembrolizumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 3, Pp 114-119 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	immunotherapy colon cancer microsatellite instability anti-pd-1 monoclonal antibodies nivolumab pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immunotherapy colon cancer microsatellite instability anti-pd-1 monoclonal antibodies nivolumab pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 G. A. Khakimov A. A. Tryakin G. G. Khakimova Use of nivolumab for colon cancer with Lynch syndrome
description	Lynch syndrome (LS), which occurs as a result of the defects in DNA mismatch repair, is characterized by an increased risk of colon, endometrial and urinary tract cancers. It is known that in case of colorectal cancer, the presence of high-frequency microsatellite instability (MSI-H) is associated with better survival rates, independent of other prognostic factors, including the stage of tumor development. Thus, in stage II sporadic colorectal cancer, MSI-H occurs in 22% of cases, in stage III in 12% of cases, and in stage IV only in 2% of cases. Regardless of the type of the tumor, immunotherapy using checkpoint inhibitors has been approved for treating patients with unresectable or metastatic tumors with deficient DNA mismatch repair (dMMR), this fact can be used as an approach to treatment patients with LS. The article describes the clinical observation of the patient with germline mutation in MLH1 gene, suffering from multiple primary malignancies of the colon, who has been receiving nivolumab for 26 months. This observation demonstrates the success of immunotherapy after sixth-line chemotherapy, showing the potential control of tumor growth in patients with LS.
format	article
author	G. A. Khakimov A. A. Tryakin G. G. Khakimova
author_facet	G. A. Khakimov A. A. Tryakin G. G. Khakimova
author_sort	G. A. Khakimov
title	Use of nivolumab for colon cancer with Lynch syndrome
title_short	Use of nivolumab for colon cancer with Lynch syndrome
title_full	Use of nivolumab for colon cancer with Lynch syndrome
title_fullStr	Use of nivolumab for colon cancer with Lynch syndrome
title_full_unstemmed	Use of nivolumab for colon cancer with Lynch syndrome
title_sort	use of nivolumab for colon cancer with lynch syndrome
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/b99da209ccc44f37985e2d2943ad2e92
work_keys_str_mv	AT gakhakimov useofnivolumabforcoloncancerwithlynchsyndrome AT aatryakin useofnivolumabforcoloncancerwithlynchsyndrome AT ggkhakimova useofnivolumabforcoloncancerwithlynchsyndrome
_version_	1718406404424859648

Use of nivolumab for colon cancer with Lynch syndrome

Ejemplares similares